Elsevier

Advanced Drug Delivery Reviews

Volume 126, 15 February 2018, Pages 162-176
Advanced Drug Delivery Reviews

Wound healing in the eye: Therapeutic prospects

https://doi.org/10.1016/j.addr.2018.01.006Get rights and content

Abstract

In order to maintain a smooth optical surface the corneal epithelium has to continuously renew itself so as to maintain its function as a barrier to fluctuating external surroundings and various environmental insults. After trauma, the cornea typically re-epithelializes promptly thereby minimizing the risk of infection, opacification or perforation. A persistent epithelial defect (PED) is usually referred to as a non-healing epithelial lesion after approximately two weeks of treatment with standard therapies to no avail. They occur following exposure to toxic agents, mechanical injury, and ocular surface infections and are associated with significant clinical morbidity in patients, resulting in discomfort or visual loss. In the case of deeper corneal injury and corneal pathology the wound healing cascade can also extend to the corneal stroma, the layer below the epithelium. Although significant progress has been made in recent years, pharmaco-therapeutic agents that promote corneal healing remain limited. This article serves as a review of current standard therapies, recently introduced alternative therapies gaining in popularity, and a look into the newest developments into ocular wound healing.

Introduction

This review will consider two aspects of wound healing in the eye: repair and maintenance of the corneal epithelium which faces the external environment, and maintenance of the corneal stroma which provides the cornea‘s structural integrity.

To maintain a smooth optical surface, the corneal epithelium has to continuously renew itself to function as a barrier to fluctuating external surroundings and various environmental insults. After trauma the cornea typically re-epithelializes promptly, minimizing the risk of infection, opacification or perforation. In the presence of certain risk factors such as dry eye disease, diabetic keratopathy, ocular cicatrizing disorders, limbal stem cell deficiency (LSCD), chemical injury, exposure keratopathy, and neurotrophic keratopathy from prior herpetic keratitis or previous keratoplasty; epithelial defects can persist. A persistent epithelial defect (PED) is usually referred to a non-healing epithelial lesion after approximately two weeks of treatment with standard therapies to no avail [1]. They occur following exposure to toxic agents, mechanical injury or ocular surface infections and are associated with significant clinical morbidity in patients, resulting in discomfort or visual loss. The incidence of PEDs is unknown but estimated to about 200,000 per annum in the USA although significantly higher in some other parts of the world. Management of patients with PEDs can be challenging and may require an extended treatment and follow-up period. Although significant progress has been made in recent years, pharmaco-therapeutic agents that promote epithelial healing remain limited. In this article a review of current standard therapies, recently introduced alternative therapies gaining in popularity, and a look into the newest developments into ocular surface wound healing is given.

The corneal epithelium is an ectoderm derived, non-keratinized, stratified layer with a unique cytokeratin expression pattern and a reported thickness of between 48 and 53 μm [2,3]. The corneal epithelium is a barrier composed of a series of tightly networked cells seven to eight cell layers thick and attached to the basal lamina through hemidesmosomes. Cells are attached to each other with desmosomes and communicate both within and between layers via gap junctions. The epithelium serves as the eyes first line of defense against trauma. It is a fast regenerating tissue that is maintained by the integrity and functionality of a specialized stem cell population, known as limbal stem cells (LSCs). LCS are said to be located in the basal layer of the palisades of Vogt of the limbus, a narrow transition zone surrounding the cornea [4].

Regeneration of the corneal epithelial surface after an intrinsic or extrinsic insult appear to involve division, migration, and maturation of LSCs. The XYZ hypothesis proposes that the maintenance of the corneal epithelium can be represented by the formula X + Y = Z, where Z (desquamation), is the sum of X (proliferation) and Y (centripetal migration) (Fig. 1) [5,6].

The wound healing response in the cornea is a convoluted process. An intrinsic cascade involving autocrine and paracrine cytokine mediated interactions between epithelial cells, stromal keratocytes, corneal nerves, and cells of the immune system control this process. The tissue wound healing response also varies depending on the severity of the inciting injury. Upon injury, epithelial cells evoke sequential steps attempting to efficiently seal the wound and to prevent potential opportunistic infection that can result in devastation of the eye. Epithelial wound healing occurs in a phased process with specific physiological functions [7].

In the latent phase there is no movement of cells or any apparent change in cell numbers but there is reported to be an increase in metabolic activity and a reorganization of cell structures is observed [8,9]. This is accompanied by an increased synthesis of several cytoskeletal proteins with several integrins e.g. α6 and β4, located at the basal area of epithelial cells responsible for the linkage of cytoskeletal components to the underlying basement membrane [10]. In the migration phase, cells around the wound edge migrate across and cover the denuded area [11], a process which requires the synthesis of an array of actin-rich stress fibers in the cytoplasm and which can be readily blocked if topical anesthetic drugs are used [12]. This is followed by the cell proliferation stage in which epithelial cells divide and differentiate in order to restore the epithelium's original structure and complete with intercellular junctions [13]. The proliferative response appears to be compartmentalized to the limbal region with cells at the leading edge not showing an increased rate of proliferation [14]. The last phase is characterized by the establishment of cell to substrate attachments as the epithelium is stabilised and is no longer motile [15]. These phases are often overlapping and allow for the coverage of the wounded epithelium, restoration of normal cell density and reformation of cell attachments. PEDs occur when there is a failure of mechanisms which promote corneal epithelialization.

The first step in the management of any epithelial abnormality is to determine and address the underlying aetiology. Numerous pharmacological agents are currently employed to modify wound healing in patients with a PED. Patients are currently treated using a step ladder management approach utilizing a series of interventions. We will now review some of the currently available and emerging pharmaceutical agents. It is beyond the scope of this article to discuss surgical treatment options such as tarsorrhaphy, therapeutic excimer laser ablation and amniotic membrane transplantation.

Section snippets

Discontinuation of medication

The first goal when dealing with a PED is to provide the eye with an environment conducive to the innate healing ability of the ocular surface. An often overlooked cause of poor ocular healing is “medicamentosa” or toxic keratitis stemming from topical ophthalmic medication or preservatives in eye drops. Preservatives such as benzalkonium chloride (BAK) and Polyquarternium-1 are typical culprits as they are almost ubiquitously deployed in ophthalmic preparations and have consistently been shown

Growth factor derived products

Several growth factors including epidermal growth factor (EGF), keratinocyte growth factor 1 (KGF-1), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), transforming growth factor-β (TGF-β), and hepatocyte growth factor (HGF) are actively involved in corneal wound healing [53]. These low molecular weight molecules are strong mitogens of corneal epithelial cells and can enhance corneal epithelial proliferation after local administration to the eye

Wound healing in the corneal stroma and keratoconus

One of the first observable changes following injury to the corneal stroma is the death of a subpopulation of keratocytes surrounding the injury site. This initial response is thought to prevent inflammation in the rest of the cornea. Apoptosis is induced by cytokines such as interleukin-1 which is secreted from the overlying epithelium. About 6 h after injury the process of repair begins with the first event being the transition of the keratocytes around the wound edge to an activated

Conclusion

In this review, we have discussed current and emerging therapies for ocular surface wound healing. Despite the advances made in this field there remains a real need for new and improved pharmacotherapeutic agents. The healing of ocular surface wounds is a complex process involving the interaction of cells, receptors, enzyme systems, cytokines and the components of the extracellular matrix. Recent advances in understanding the processes involved in the wound healing response and the molecules

References (260)

  • M.T. Drobbin et al.

    Dexamethasone does not alter in vitro antibacterial efficacy of gentamicin

    Otolaryngol. Head Neck Surg.

    (2007)
  • Y.K. Lee et al.

    Therapeutic outcomes of combined topical autologous serum eye drops with silicone-hydrogel soft contact lenses in the treatment of corneal persistent epithelial defects: a preliminary study

    Cont. Lens Anterior Eye

    (2016)
  • S.J. Blackmore

    The use of contact lenses in the treatment of persistent epithelial defects

    Cont. Lens Anterior Eye

    (2010)
  • R. Arora et al.

    Efficacy of continuous wear PureVision contact lenses for therapeutic use

    Cont. Lens Anterior Eye

    (2004)
  • P. Rosenthal et al.

    Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens

    Am J. Ophthalmol.

    (2000)
  • P. Lim et al.

    Treatment of persistent corneal epithelial defect with overnight wear of a prosthetic device for the ocular surface

    Am J. Ophthalmol.

    (2013)
  • F.S. Yu et al.

    Growth factors and corneal epithelial wound healing

    Brain Res. Bull.

    (2010)
  • Y.C. Wu et al.

    Elevated IGFBP3 levels in diabetic tears: a negative regulator of IGF-1 signaling in the corneal epithelium

    Ocul. Surf.

    (2012)
  • T. Chikama et al.

    Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I

    Lancet

    (1998)
  • S.S. Riaz et al.

    Neurotrophic factors in peripheral neuropathies: pharmacological strategies

    Prog. Neurobiol.

    (1996)
  • A. Micera et al.

    Nerve growth factor effect on human primary fibroblastic-keratocytes: possible mechanism during corneal healing

    Exp. Eye Res.

    (2006)
  • S. Bonini et al.

    Topical treatment with nerve growth factor for neurotrophic keratitis

    Ophthalmology

    (2000)
  • W. Chen et al.

    Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes

    J. Biol. Chem.

    (2011)
  • H.S. Dua et al.

    The amniotic membrane in ophthalmology

    Surv. Ophthalmol.

    (2004)
  • T. John et al.

    Amniotic membrane in the surgical management of acute toxic epidermal necrolysis

    Ophthalmology

    (2002)
  • J.P. McCulley et al.

    Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group

    Trans. Am. Ophthalmol. Soc.

    (1993)
  • Y. Oie et al.

    Regenerative medicine for the cornea

    Biomed. Res. Int.

    (2013)
  • R.A. Thoft et al.

    The X, Y, Z hypothesis of corneal epithelial maintenance

    Invest. Ophthalmol. Vis. Sci.

    (1983)
  • M. Haagdorens et al.

    Limbal stem cell deficiency: current treatment options and emerging therapies

    Stem Cells Int.

    (2016)
  • V.B. Agrawal et al.

    Corneal epithelial wound healing

    Indian J. Ophthalmol.

    (2003)
  • C.E. Crosson et al.

    Epithelial wound closure in the rabbit cornea. A biphasic process

    Invest. Ophthalmol. Vis. Sci.

    (1986)
  • J.D. Zieske et al.

    Protein synthesis during corneal epithelial wound healing

    Invest. Ophthalmol. Vis. Sci.

    (1986)
  • T. Kuwabara et al.

    Sliding of the epithelium in experimental corneal wounds

    Investig. Ophthalmol.

    (1976)
  • E.H. Chung et al.

    Synchronization of the G1/S transition in response to corneal debridement

    Invest. Ophthalmol. Vis. Sci.

    (1999)
  • I.K. Gipson et al.

    Reassembly of the anchoring structures of the corneal epithelium during wound repair in the rabbit

    Invest. Ophthalmol. Vis. Sci.

    (1989)
  • R. Noecker

    Effects of common ophthalmic preservatives on ocular health

    Adv. Ther.

    (2001)
  • M. Ayaki et al.

    Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells

    Clin. Exp. Ophthalmol.

    (2008)
  • S. Miyauchi et al.

    The effect of sodium hyaluronate on the migration of rabbit corneal epithelium. I. An in vitro study

    J. Ocul. Pharmacol.

    (1990)
  • T. Sugiyama et al.

    The effect of sodium hyaluronate on the migration of rabbit corneal epithelium. II. The effect of topical administration

    J. Ocul. Pharmacol.

    (1991)
  • B. Wirostko et al.

    Novel therapy to treat corneal epithelial defects: a hypothesis with growth hormone

    Ocul. Surf.

    (2015)
  • S. Tomas-Barberan et al.

    Influence of topical treatment on epithelial wound healing and pain in the early postoperative period following photorefractive keratectomy

    Acta Ophthalmol. Scand.

    (1999)
  • A. Sugar et al.

    A randomized trial of topical corticosteroids in epithelial healing after keratoplasty

    Cornea

    (1984)
  • R. Rask et al.

    Healing velocity of corneal epithelium evaluated by computer. The effect of topical steroid

    Acta Ophthalmol. Scand.

    (1995)
  • F. Yulek et al.

    Effect of topical steroids on corneal epithelial healing after vitreoretinal surgery

    Acta Ophthalmol. Scand.

    (2006)
  • H.M. Leibowitz et al.

    Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis

    Arch. Ophthalmol.

    (1977)
  • H.M. Leibowitz et al.

    Topically administered corticosteroids: effect on antibiotic-treated bacterial keratitis

    Arch. Ophthalmol.

    (1980)
  • L.S. Engel et al.

    Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis

    Curr. Eye Res.

    (1995)
  • T.R. Carmichael et al.

    Topical steroids in the treatment of central and paracentral corneal ulcers

    Br. J. Ophthalmol.

    (1990)
  • F. van Klink et al.

    The role of contact lenses, trauma, and Langerhans cells in a Chinese hamster model of Acanthamoeba keratitis

    Invest. Ophthalmol. Vis. Sci.

    (1993)
  • P. Rosenthal et al.

    Fluid-ventilated, gas-permeable scleral contact lens is an effective option for managing severe ocular surface disease and many corneal disorders that would otherwise require penetrating keratoplasty

    Eye Contact Lens

    (2005)
  • Cited by (0)

    View full text